Jingde Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jingde Wu has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
Feng He
Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Science, Shandong University, 44 West Wenhua Road, 250012 Ji'nan, Shandong, PR China
9 shared publicationsAna Xu
Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, PR China
8 shared publicationsXiangna Zhang
Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, PR China
8 shared publicationsChao Wei
Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, PR China
7 shared publicationsChenggong Yu
Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Science, Shandong University, 44 West Wenhua Road, 250012 Ji'nan, Shandong, PR China
7 shared publicationsJiahui Lv
Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Science, Shandong University, 44 West Wenhua Road, 250012 Ji'nan, Shandong, PR China
7 shared publications
Latest Publications
- 25 May 2026
- Published by Elsevier in Bioorganic Chemistry
- Vol. 179, 110034
Development of novel quinoline derivatives as selective HDAC6 inhibitors exhibiting multiple anticancer effects
- 25 May 2026
- Published by Elsevier in Bioorganic Chemistry
- Vol. 179, 110034
Development of novel quinoline derivatives as selective HDAC6 inhibitors exhibiting multiple anticancer effects
- Open Access
- 24 February 2026
- Published by Elsevier in SSRN Electronic Journal
Development of Novel Quinoline Derivatives as Selective HDAC6 Inhibitors Exhibiting Multiple Anticancer Effects
Histone deacetylase 6 (HDAC6) is an important player in the cellular process. Overexpression of HDAC6 is associated with tumorigenesis and becomes a major cause of death in patients with cancers. Herein, Optimization of the lead compound MPT0G211 yielded a potent HDAC6 inhibitor, P21, with significantly improved potency and selectivity over other isoforms Western blot analysis further confirmed that the compound selectively increased the acetylation levels of α-tubulin without affecting histone H3. Furthermore, compound P21 exhibited potent anti-proliferative, anti-invasive, and anti-angiogenic activities, alongside the induction of apoptosis and cell cycle arrest. Notably, it demonstrated significant anti-proliferative efficacy in vivo in a patient-derived xenograft (PDX) mouse model. Collectively, the results strongly encourage further development of P21 as an anticancer agent.
- 24 February 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessDevelopment of Novel Quinoline Derivatives as Selective HDAC6 Inhibitors Exhibiting Multiple Anticancer Effects
Histone deacetylase 6 (HDAC6) is an important player in the cellular process. Overexpression of HDAC6 is associated with tumorigenesis and becomes a major cause of death in patients with cancers. Herein, Optimization of the lead compound MPT0G211 yielded a potent HDAC6 inhibitor, P21, with significantly improved potency and selectivity over other isoforms Western blot analysis further confirmed that the compound selectively increased the acetylation levels of α-tubulin without affecting histone H3. Furthermore, compound P21 exhibited potent anti-proliferative, anti-invasive, and anti-angiogenic activities, alongside the induction of apoptosis and cell cycle arrest. Notably, it demonstrated significant anti-proliferative efficacy in vivo in a patient-derived xenograft (PDX) mouse model. Collectively, the results strongly encourage further development of P21 as an anticancer agent.
- 17 October 2024
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 280, 116972
HDAC8 as a target in drug discovery: Function, structure and design
- 17 October 2024
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 280, 116972
HDAC8 as a target in drug discovery: Function, structure and design
- 10 September 2024
- Published by Elsevier in Bioorganic Chemistry
- Vol. 153, 107818
HDAC6 mediates tumorigenesis during mitosis and the development of targeted deactivating agents
- 10 September 2024
- Published by Elsevier in Bioorganic Chemistry
- Vol. 153, 107818
HDAC6 mediates tumorigenesis during mitosis and the development of targeted deactivating agents
- 22 May 2023
- Published by Elsevier in Bioorganic Chemistry
- Vol. 138, 106622
Recent development of selective inhibitors targeting the HDAC6 as anti-cancer drugs: Structure, function and design
- 22 May 2023
- Published by Elsevier in Bioorganic Chemistry
- Vol. 138, 106622
Recent development of selective inhibitors targeting the HDAC6 as anti-cancer drugs: Structure, function and design
- 21 January 2023
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 80, 117178
Design, synthesis, and biological evaluation of novel N-Benzyl piperidine derivatives as potent HDAC/AChE inhibitors for Alzheimer’s disease
- 21 January 2023
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 80, 117178
Design, synthesis, and biological evaluation of novel N-Benzyl piperidine derivatives as potent HDAC/AChE inhibitors for Alzheimer’s disease
- 9 August 2022
- Published by Elsevier in Bioorganic Chemistry
- Vol. 128, 106090
Recent advances of small molecule JNK3 inhibitors for Alzheimer’s disease
- 9 August 2022
- Published by Elsevier in Bioorganic Chemistry
- Vol. 128, 106090
Recent advances of small molecule JNK3 inhibitors for Alzheimer’s disease
- 9 July 2022
- Published by Elsevier in Bioorganic Chemistry
- Vol. 128, 106010
Design, synthesis and biological evaluation of phenyl vinyl sulfone based NLRP3 inflammasome inhibitors
- 9 July 2022
- Published by Elsevier in Bioorganic Chemistry
- Vol. 128, 106010
Design, synthesis and biological evaluation of phenyl vinyl sulfone based NLRP3 inflammasome inhibitors
- 1 March 2022
- Published by Royal Society of Chemistry (RSC) in Organic Chemistry Frontiers
- Vol. 9 (8) , 2121-2128
Asymmetric decarboxylative [3 + 2] cycloaddition for the diastereo- and enantioselective synthesis of spiro[2.4]heptanes via cyclopropanation
A novel asymmetric [3 + 2] cycloaddition reaction of 1,4-dipoles and nitroolefins catalysed by the cooperative action of the chiral palladium/phosphine complex and the chiral urea-tertiary amine is described.
- 1 March 2022
- Published by Royal Society of Chemistry (RSC) in Organic Chemistry Frontiers
- Vol. 9 (8) , 2121-2128
Asymmetric decarboxylative [3 + 2] cycloaddition for the diastereo- and enantioselective synthesis of spiro[2.4]heptanes via cyclopropanation
A novel asymmetric [3 + 2] cycloaddition reaction of 1,4-dipoles and nitroolefins catalysed by the cooperative action of the chiral palladium/phosphine complex and the chiral urea-tertiary amine is described.
- 1 January 2022
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 228, 114037
A branched small molecule-drug conjugate nanomedicine strategy for the targeted HCC chemotherapy
- 1 January 2022
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 228, 114037
A branched small molecule-drug conjugate nanomedicine strategy for the targeted HCC chemotherapy